For full prescribing information, kindly refer to the approved package insert
S4 FORXIGA® 5 mg (tablets) Reg. No. 46/21.2/0214. Each tablet contains the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol. Contains lactose anhydrous.
S4 FORXIGA® 10 mg (tablets) Reg. No. 46/21.2/0215. Each tablet contains the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. Contains lactose anhydrous.
PHARMACOLOGICAL CLASSIFICATION:A 21.2 Oral hypoglycaemics.
INDICATIONS: FORXIGA ® is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on combination therapy.
WARNINGS AND PRECAUTIONS: Reports of metabolic acidosis, including ketoacidosis, which were serious life-threatening or fatal, in patients taking FORXIGA
®. Patients who present with signs and symptoms, should discontinue FORXIGA® and the patient should be promptly evaluated and managed accordingly
AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07
Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa.
Private Bag X23, Bryanston, 2021, South Africa.
Tel: 011 797-6000. Fax: 011 797-6001. www.astrazeneca.co.za.
Activity ID: ZA-1590. Expiry Date: October 2020
Legal Notice and Terms of Use | Cookies | Privacy Notice | References
